BrandiNReevesMD

Hematologic Oncology

Assistant Professor

Dr. Reeves is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 984-974-2602

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2011 - 2014
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2008 - 2011
University of Cincinnati College of MedicineClass of 2008

PubMed

Abstracts/Posters

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Result...
Brandi Reeves, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Brandi Reeves, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

$Melflufen plus Dexamethasone in relapsed/refractory Multiple Myeloma: Long‐Term Survival Follow‐up from the Phase II Study O‐12‐M1$
Melflufen plus Dexamethasone in relapsed/refractory Multiple Myeloma: Long‐Term Survival Follow‐up from the Phase II Study O‐12‐M1January 6th, 2021
Effects of Ibrutinib Treatment on Murine Platelet Func- Tion During Inflammation and in Primary HemostasisMarch 2nd, 2017